Global Macular Degeneration Treatment Market Growth (Status and Outlook) 2023-2029

Global Macular Degeneration Treatment Market Growth (Status and Outlook) 2023-2029

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.

LPI (LP Information)' newest research report, the “Macular Degeneration Treatment Industry Forecast” looks at past sales and reviews total world Macular Degeneration Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Macular Degeneration Treatment sales for 2023 through 2029. With Macular Degeneration Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Macular Degeneration Treatment industry.

This Insight Report provides a comprehensive analysis of the global Macular Degeneration Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Macular Degeneration Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Macular Degeneration Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Macular Degeneration Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Macular Degeneration Treatment.

The global Macular Degeneration Treatment market size is projected to grow from US$ 5821.5 million in 2022 to US$ 7524.9 million in 2029; it is expected to grow at a CAGR of 3.7% from 2023 to 2029.

United States market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Macular Degeneration Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Macular Degeneration Treatment players cover Bausch Health Companies, Allergan, Novartis, Pfizer, Bayer, Roche, Sanofi, Santen Pharmaceuticals and Regeneron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Macular Degeneration Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Lucentis
Eylea
Avastin
Others

Segmentation by application
Hospitals
Eye Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bausch Health Companies
Allergan
Novartis
Pfizer
Bayer
Roche
Sanofi
Santen Pharmaceuticals
Regeneron Pharmaceuticals
Kanghong Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.